Citations (10)
Invitrogen™ Silencer™ Pre-designed siRNAs are available for all human, mouse, and rat gene targets in the RefSeq database. These siRNAs are designed for maximum potency and specificity using a highly effective and extensively tested algorithm. Each siRNA is synthesized to the highest quality standards and is provided with full sequence information. Furthermore, when you purchase three Silencer Pre-Designed siRNAs to the same target, we guarantee that with at least two of the siRNAs you will achieve >70% reduction in target mRNA levels.
Libraries
Silencer Validated siRNAs
A subset of Invitrogen™ Ambion™ siRNAs to human targets have been functionally tested in house and verified to reduce target mRNA levels by 70% or greater, enabling us to guarantee that these Silencer Validated siRNAs will knock-down their target genes. The data sheet provided with each of these siRNAs shows the extent of mRNA knockdown observed during testing and the exon targeted by the siRNA. For most types, full sequence information is also provided at no additional charge.
For Next Generation pre-designed & validated siRNAs that incorporate the latest improvements in siRNA design, off-target effect prediction algorithms, and chemical modifications to yield siRNAs with unrivalled efficacy, potency, and specificity, please see Silencer Select Pre-Designed & Validated siRNAs.
Optimized Design + High Quality Synthesis = Guaranteed Silencing
Silencer Pre-Designed and Validated siRNAs are designed for maximum potency and specificity using a proprietary algorithm developed by Cenix BioScience and owned by Ambion (see siRNA Design: It's All in the Algorithm). Cenix and Ambion directly measured the effectiveness of approximately 1,100 algorithm-designed siRNAs in the silencing of almost 400 endogenously expressed human transcripts. This comprehensive survey indicated that, on a per siRNA basis, more than 80% of the individual siRNAs showed >70% silencing of their target. The performance data clearly confirm the success of the Ambion siRNA selection process.
We synthesize and purify each siRNA in state-of-the-art facilities to meet the highest quality standards. As part of our rigorous quality control procedures, each RNA oligonucleotide is analyzed by MALDI-TOF mass spectrometry and/or analytical HPLC. To provide the utmost in quality, Ambion also assesses each annealed siRNA by gel electrophoresis to confirm that the strands annealed properly. The result is premium quality siRNA that is purified and ready to use.
Approximate Turnaround Times*
| Standard purification | 4 business days |
| HPLC purification | 6 business days (20 and 40 nmol) 8 business days (160 nmol) |
| In Vivo Ready | 12 business days (100 and 250 nmol) 15 business days (1 µmol) 20 business days (10 µmol) |
| Cy3 and FAM labeled | 8 business days |
*Estimated time from order confirmation to ship date from Austin, TX for orders confirmed by 2 pm CST. Does not include time required for shipping (typically overnight for US and Canada deliveries, 2 days for Europe, 2-3 days elsewhere).
Search More Than 200,000 Ambion siRNAs
|
Search our more than 200,000 Ambion siRNAs |
- Name: lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements.
Authors: Gong C, Maquat LE
Journal: Nature. 2011 Feb 10;470(7333):284-8 - Name: Systems survey of endocytosis by multiparametric image analysis.
Authors: Collinet C, Stöter M, Bradshaw CR, Samusik N, Rink JC, Kenski D, Habermann B, Buchholz F, Henschel R, Mueller MS, Nagel WE, Fava E, Kalaidzidis Y, Zerial M
Journal: Nature. 2011 Feb 10;470(7333):284-8 - Name: Functional genomic screen for modulators of ciliogenesis and cilium length.
Authors: Kim J, Lee JE, Heynen-Genel S, Suyama E, Ono K, Lee K, Ideker T, Aza-Blanc P, Gleeson JG
Journal: Nature. 2010 Apr 15;464(7291):1048-51 - Name: Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes.
Authors: Neumann B, Walter T, Hériché JK, Bulkescher J, Erfle H, Conrad C, Rogers P, Poser I, Held M, Liebel U, Cetin C, Sieckmann F, Pau G, Kabbe R, Wünsche A, Satagopam V, Schmitz MH, Chapuis C, Gerlich DW, Schneider R, Eils R, Huber W, Peters JM, Hyman AA, Durbin R, Pepperkok R, Ellenberg J
Journal: Nature. 2010 Apr 1;464(7289):721-7 - Name: Genome-wide silencing in Drosophila captures conserved apoptotic effectors
Authors: Chew SK, Chen P, Link N, Galindo KA, Pogue K, Abrams JM
Journal: Nature. 2009 Jul 2;460(7251):123-7 - Name: Drosophila RNAi screen identifies host genes important for influenza virus replication
Authors: Hao L. et. al.
Journal: Nature. 2008 August 14 - Name: Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein.
Authors: Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF
Journal: Nat Biotechnol. 2009 Jun;27(6):567-71. - Name: Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.
Authors: O'Neill E, Rushworth L, Baccarini M, Kolch W
Journal: Science. 2004 Dec 24;306(5705):2267-70. - Name: A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network
Authors: Lunardi A, Di Minin G, Provero P, Dal Ferro M, Carotti M, Del Sal G, Collavin L
Journal: Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6322-7 - Name: Discovery of a lysophospholipid acyltransferase family essential for membrane asymmetry and diversity
Authors: Hishikawa D. et.al
Journal: PNAS 2008